Related references
Note: Only part of the references are listed.Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer
Carmen E. Gomez et al.
CURRENT GENE THERAPY (2008)
Randomized phase III trial comparing bexarotene (L106949)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I
Rodryg Ramlau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) - A phase 2 trial
Robert J. Amato et al.
JOURNAL OF IMMUNOTHERAPY (2008)
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer
Rodryg Ramlau et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Modified vaccinia virus Ankara as a vector for suicide gene therapy
P. Erbs et al.
CANCER GENE THERAPY (2008)
An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses
A. Fournillier et al.
VACCINE (2007)
5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy
Robert J. Amato
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
Sarah C. Gilbert et al.
VACCINE (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
MUC1 as a target antigen for cancer immunotherapy
B Acres et al.
EXPERT REVIEW OF VACCINES (2005)
Intraductal papillary mucinous tumors of the pancreas
KC Conlon
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)
RG Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Fighting cancer with vaccinia virus: Teaching new tricks to an old dog
YQ Shen et al.
MOLECULAR THERAPY (2005)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
CL Smith et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
M Mwau et al.
JOURNAL OF GENERAL VIROLOGY (2004)
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination:: A phase I trial in metastatic melanoma
M Di Nicola et al.
CLINICAL CANCER RESEARCH (2004)
Phase 1 trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer
AJ Pantuck et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
C Rochlitz et al.
JOURNAL OF GENE MEDICINE (2003)
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
SJ McConkey et al.
NATURE MEDICINE (2003)
Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2
KT Trevor et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer
SM Scholl et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
